The Food and Drug Administration (FDA) will host a public advisory committee meeting of the Cardiovascular and Renal Drugs Advisory Committee on February 24, 2025. The committee's role is to advise the FDA on regulatory matters. The meeting, which will take place in Silver Spring, MD, and online, is open to the public. The FDA invites public comments until February 21, 2025, regarding the meeting, which is about evaluating a new drug application by Novartis Pharmaceuticals for the treatment of adults with complement 3 glomerulopathy (C3G).
Simple Explanation
The FDA is having a meeting on February 24, 2025, where they will talk about a new medicine for kidney problems called C3G, and everyone is welcome to join online or in person to share their thoughts. People can tell the FDA what they think about this medicine until February 21, 2025, and if too many people want to speak at the meeting, the FDA might choose speakers by drawing names.